Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Dicembre 2023 - 10:30PM
Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company
focused on developing next-generation therapeutics to target
difficult-to-treat cancers, reported today that Pyxis Oncology’s
Compensation Committee of the Board of Directors approved a stock
option grant to Ken Kobayashi, M.D., the Company’s newly appointed
Chief Medical Officer, in connection with his employment with the
Company effective on November 27, 2023. The equity award was
granted under the Pyxis Oncology, Inc. 2022 Inducement
Plan with a grant date of December 29, 2023, as an inducement
material to Dr. Kobayashi entering into employment with Pyxis
Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
The option to purchase 443,514 shares of Pyxis Oncology’s common
stock will vest over four years, with 25% vesting on the first
anniversary of the vesting commencement date and the remaining
shares vesting monthly over the 36-month period thereafter, subject
to Dr. Kobayashi’s continued employment with the Company through
the applicable vesting dates. The option to purchase 110,878 shares
of the Company’s common stock will vest upon Dr. Kobayashi’s
achievement of certain clinical milestones related to data
disclosure for PYX-201. The stock options have a ten-year term and
an exercise price of $1.80, the closing price of Pyxis Oncology’s
common stock as reported by Nasdaq on December 29, 2023.
Pyxis Oncology is providing this information in accordance with
Nasdaq Listing Rule 5635(c)(4).
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage company focused on
defeating difficult-to-treat cancers. The company is efficiently
building next-generation therapeutics that hold the potential for
mono and combination therapies. Pyxis Oncology’s therapeutic
candidates are designed to directly kill tumor cells and to address
the underlying pathologies created by cancer that enable its
uncontrollable proliferation and immune evasion. Pyxis Oncology’s
antibody-drug conjugates (ADCs) and immuno-oncology (IO) programs
employ novel and emerging strategies to target a broad range of
solid tumors resistant to current standards of care. To learn more,
visit www.pyxisoncology.com or follow us
on Twitter and LinkedIn.
Pyxis Oncology Contact
Pamela ConnealyCFO and COOir@pyxisoncology.com
Grafico Azioni Pyxis Oncology (NASDAQ:PYXS)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Pyxis Oncology (NASDAQ:PYXS)
Storico
Da Dic 2023 a Dic 2024